Structure Therapeutics Inc. (GPCR) SEC Filings & Earnings Calls
EquiReason read 10 Structure Therapeutics Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-09-08 — Positive topline results for oral amylin agonist (ACCG-2671) and GLP-1 agonist (aleniglipron) in chronic weight management; 72-week OLE data..
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
6 Aug 202610-QQuarterly report showing continued losses and no revenue; no beat or miss context provided.earningsopen
Figures in the filing · each found in the filing text
| Net Loss · H1-2026 | $-182M | |
| Accumulated Deficit · 2026-06-30 | $652M |
Risks flagged
No approved products or revenue; history of losses
“We have no products approved for commercial sale and have not generated any revenue to date, and we continue to incur significant research and development and other expenses related to our ongoing operations.” · word for word
Dependence on third-party manufacturers in China; tariff exposure
“Currently, the active pharmaceutical ingredients (“APIs”) and drug product are manufactured in China.” · word for word
Significant dilution risk from ATM facility
“approximately $341.5 million remained available for sale” · word for word
Clinical trial and regulatory uncertainty
“We are early in our development efforts and only have four product candidates in early clinical development — aleniglipron, ACCG-2671, ACCG-3535 and LTSE-2578.” · word for word
6 Aug 20268-K · 2.02Phase 3 ACCOMPLISH program initiated for aleniglipron; Phase 1 SAD data for ACCG-2671 on track; topline data expected Q3/Q4 2026; cash $1.3B funds through 2028.open
Figures in the filing · each found in the filing text
| Cash, cash equivalents and short-term investments · Q2-2026 | $1.30B |
Risks flagged
Clinical trial risk: Phase 3 data not yet available; potential for failure.
“Topline data expected Q3/Q4 2026; no efficacy/safety results yet.”
7 May 202610-QClinical-stage biopharma reports Q1 2026 net loss of $76M, no revenue, cash runway through 2028.earningsopen
Figures in the filing · each found in the filing text
| Net Loss · Q1-2026 | $-76M | |
| Accumulated Deficit · 2026-03-31 | $546M |
Risks flagged
No approved products or revenue
“We have no products approved for commercial sale and have not generated any revenue to date” · word for word
Clinical trial failure risk
“The historical failure rate for product candidates in our industry is high.” · word for word
Dependence on Chinese manufacturing
“Currently, the active pharmaceutical ingredients (“APIs”) and drug product are manufactured in China.” · word for word
Dilution risk from ATM
“approximately $341.5 million remained available for sale under the ATM Sales Agreement” · word for word
7 May 20268-K · 1.01, 2.02, 8.01Structure Therapeutics reports positive aleniglipron Phase 2 ACCESS II results: up to 16.3% placebo-adjusted weight loss at 44 weeks, highest efficacy among oral GLP-1RAs. Positive FDA end-of-Phase 2 feedback received; Phase 3 initiation onopen
Figures in the filing · each found in the filing text
| Cash, cash equivalents and short-term investments · Q1-2026 | $1.50B | |
| Placebo-adjusted mean weight loss (180mg dose at 44 weeks) · Q1-2026 | 16.3% | |
| Placebo-adjusted mean weight loss (240mg dose at 44 weeks) · Q1-2026 | 16.0% | |
| ATM gross proceeds previously sold · Q1-2026 | $59M | |
| ATM shares previously sold · Q1-2026 | 3,040,000 |
Risks flagged
Clinical development risk: Phase 3 program yet to initiate; long-term safety and efficacy data pending.
“Phase 3 initiation on track for Q3 2026; data from ACCESS OLE and Body Composition studies expected in Q3/Q4 2026.”
Dilution risk: Amended ATM facility adds $150M capacity, potentially increasing share count.
“Amended and Restated Sales Agreement increases ATM Shares available by an additional $150,000,000, for an aggregate offering price of up to $400,000,000.”
23 Apr 2026DEF 14AProxy statement (DEF 14A) disclosing executive compensation, director elections, and shareholder proposals for 2026 annual meeting.open
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-141M | |
| Net loss · FY2024 | $-123M | |
| Net loss · FY2023 | $-90M |
Risks flagged
Pre-commercial stage; no revenue or profits
“As a pre-commercial biopharmaceutical company, we do not have material revenue or profits at this stage and our success is best measured by achievement of research and development milestones.” · word for word
Clinical trial failure risk
“Our most advanced product candidate, aleniglipron (GSBR-1290), is an oral small molecule selective GLP-1 receptor agonist currently being evaluated in Phase 2 clinical trials for obesity.” · word for word
Dependence on key personnel
“The Compensation Committee and the Board determined that these salary increases were appropriate to maintain market competitiveness.” · word for word
26 Feb 20268-K · 2.02Structure Therapeutics: positive Phase 2b ACCESS data for aleniglipron (GLP-1) showing up to 15.3% weight loss at 36 weeks. Phase 3 initiation expected 2H 2026. Cash $1.4B provides runway through 2028. Amylin program advancing.open
Figures in the filing · each found in the filing text
| Cash, Cash Equivalents and Short-term Investments · Q4-2025 | $1.40B | |
| R&D Expenses · Q4-2025 | $69M | +105% y/y |
Risks flagged
Clinical development risk: Phase 3 may not replicate Phase 2 results
“Phase 3 initiation expected 2H 2026; data from ACCESS II 44-week study pending”
Competitive landscape: GLP-1 market highly competitive
“obesity market is embracing new oral treatment options”
No revenue yet; pre-commercialization stage
“pre-commercialization activities including commercial manufacturing” · word for word
26 Feb 202610-KStructure Therapeutics reported FY2025 net loss of $141.2M (increased from $122.5M in FY2024), with no revenue and an accumulated deficit of $470.3M, but cash runway through end of 2028.earningsopen
Figures in the filing · each found in the filing text
| Net loss · FY2025 | $-141M | +15% y/y |
| Accumulated deficit · FY2025 | $470M |
Risks flagged
Clinical Trial Failure Risk
“The historical failure rate for product candidates in our industry is high.” · word for word
Capital Requirement Risk
“We will require substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all.” · word for word
China Regulatory Risk
“Failure to comply with the registration procedures set forth in the SAFE Circular 37 may result in restrictions being imposed on the foreign exchange activities of the relevant onshore company.” · word for word
No Revenue or Approved Products
“We have no products approved for commercial sale and have not generated any revenue to date.” · word for word
6 Nov 20258-K · 2.02Q3 2025 net loss $65.7M vs $34.0M, R&D $59.0M vs $32.6M. Cash $799M. Key catalysts: aleniglipron topline data by year-end 2025, ACCG-2671 Phase 1 initiation. Pre-revenue biotech.earningsopen
Figures in the filing · each found in the filing text
| Net Loss · Q3-2025 | $-66M | +93% y/y |
| R&D Expenses · Q3-2025 | $59M | +81% y/y |
| Cash, Cash Equivalents and Short-Term Investments · Q3-2025 | $799M |
Risks flagged
Pre-revenue biotech with increasing R&D spend; net loss widening.
“Net loss for the third quarter of 2025 totaled $65.7 million ... compared to $34.0 million for the third quarter of 2024” · word for word
Clinical trial risk: aleniglipron data readout by year-end is binary catalyst.
“ACCESS and ACCESS II Studies on track for topline 36-week data readouts by year-end 2025” · word for word
6 Nov 202510-QQ3 2025 net loss increased to $65.7M from $34.0M in Q3 2024 due to higher R&D spending; cash position remains strong at $799M.earningsopen
Figures in the filing · each found in the filing text
| Net loss · Q3-2025 | $-66M | |
| Cash and cash equivalents · 2025-09-30 | $103M | |
| Short-term investments · 2025-09-30 | $696M |
Risks flagged
Clinical trial risk
“We are early in our development efforts and only have three product candidates, aleniglipron, ANPA-0073 and LTSE-2578, in early clinical development.” · word for word
Financing risk
“We will require substantial additional capital to finance our operations, which may not be available on acceptable terms, or at all.” · word for word
Manufacturing concentration risk
“Our APIs and drug product for our product candidates are currently provided by a supplier, WuXi STA, a subsidiary of WuXi AppTec, and we expect to rely on this supplier for the foreseeable future.” · word for word
Geopolitical risk
“Changes in the political and economic policies or in relations between China and the United States may affect our business, financial condition, results of operations and the market price of our American Depositary Shares (ADSs).” · word for word
Structure Therapeutics Inc. — questions
- What did Structure Therapeutics Inc. file recently?
- 10 SEC filings in the last 12 months. Latest: 8-K on 2026-09-08 — Positive topline results for oral amylin agonist (ACCG-2671) and GLP-1 agonist (aleniglipron) in chronic weight management; 72-week OLE data.
Every figure on this page comes from Structure Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.